Singapore launches Asia's first automated mRNA manufacturing facility

Singapore has launched Asia's first automated mRNA manufacturing facility, which will speed up vaccine production in the country. The BioFoundry can be ramped up during a health crisis, ensuring effective response to future emergencies. With its automated machines, the BioFoundry can produce enough mRNA for about 100,000 COVID-19 vaccines in just one day. Singapore invested $97 million earlier this year to position itself as a global leader in nucleic acid therapeutics (NAT) research and commercialisation.